- Home
- DV vs JANX Comparison
DV vs JANX Comparison
Compare DV & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DV
- JANX
- Stock Information
- Founded
- DV 2008
- JANX 2017
- Country
- DV United States
- JANX United States
- Employees
- DV N/A
- JANX N/A
- Industry
- DV Computer Software: Prepackaged Software
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- DV Technology
- JANX Health Care
- Exchange
- DV Nasdaq
- JANX Nasdaq
- Market Cap
- DV 3.2B
- JANX 3.0B
- IPO Year
- DV 2021
- JANX 2021
- Fundamental
- Price
- DV $19.47
- JANX $40.72
- Analyst Decision
- DV Buy
- JANX Strong Buy
- Analyst Count
- DV 20
- JANX 11
- Target Price
- DV $25.63
- JANX $83.09
- AVG Volume (30 Days)
- DV 1.8M
- JANX 1.0M
- Earning Date
- DV 02-27-2025
- JANX 03-07-2025
- Dividend Yield
- DV N/A
- JANX N/A
- EPS Growth
- DV 18.39
- JANX N/A
- EPS
- DV 0.38
- JANX N/A
- Revenue
- DV $638,459,000.00
- JANX $13,049,000.00
- Revenue This Year
- DV $19.31
- JANX $40.27
- Revenue Next Year
- DV $12.99
- JANX N/A
- P/E Ratio
- DV $51.45
- JANX N/A
- Revenue Growth
- DV 19.57
- JANX 54.12
- 52 Week Low
- DV $16.12
- JANX $7.79
- 52 Week High
- DV $43.00
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- DV 48.56
- JANX 29.72
- Support Level
- DV $19.28
- JANX $40.36
- Resistance Level
- DV $19.86
- JANX $47.46
- Average True Range (ATR)
- DV 0.54
- JANX 3.76
- MACD
- DV -0.02
- JANX -1.57
- Stochastic Oscillator
- DV 25.31
- JANX 1.70
About DV DoubleVerify Holdings Inc.
DoubleVerify Holdings Inc is a digital media measurement and analytics software platform. The DV Authentic Ad ensures that a digital ad was delivered in a brand-safe setting, completely viewable, by a real individual, and in the expected geography, is one of its solutions. It generates revenues from its advertisement customers by charging a Measured Transaction Fee on the volume of Media Transactions Measured on the software platform.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.